Department of Pharmacokinetics and Pharmacodynamics

Research output

Research output per year 1997 1999 2002 2008 2011 2017 2018 2019 2020 2021

• 64 Article
• 6 Review article
• 1 Chapter
• 1 Short survey

Research output per year

Research output per year

Search results

• 2021

  Pharmacodynamic analysis of hypertension caused by lenvatinib using real-world postmarketing surveillance data

  Otani, Y., Kasai, H. & Tanigawara, Y., 2021 Mar, In: CPT: Pharmacometrics and Systems Pharmacology. 10, 3, p. 188-198 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • lenvatinib 100%
  • Pharmacodynamics 96%
  • Hypertension 93%
  • Surveillance 77%
  • Angiotensin 57%
  3 Citations (Scopus)

• Prediction of Fracture Risk From Early-Stage Bone Markers in Patients With Osteoporosis Treated With Once-Yearly Administered Zoledronic Acid

  Kasai, H., Mori, Y., Ose, A., Shiraki, M. & Tanigawara, Y., 2021 May, In: Journal of Clinical Pharmacology. 61, 5, p. 606-613 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Zoledronic Acid 100%
  • Tartrate-Resistant Acid Phosphatase 98%
  • Bone Density 69%
  • Osteoporosis 67%
  • Bone and Bones 45%
  5 Citations (Scopus)

• Prospective evaluation and refinement of an S-1 dosage formula based on renal function for clinical application

  Takeuchi, M., Imamura, C. K., Booka, E., Takeuchi, H., Mizukami, T., Kawakami, T., Funakoshi, T., Wakuda, K., Aoki, Y., Hamamoto, Y., Kitago, M., Kawakubo, H., Boku, N., Tanigawara, Y. & Kitagawa, Y., 2021 Feb, In: Cancer science. 112, 2, p. 751-759 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Kidney 100%
  • Body Surface Area 89%
  • Fluorouracil 76%
  • Nomograms 64%
  • Pharmacokinetics 60%
  4 Citations (Scopus)
• 2020

  CYP2D6 genotype-guided tamoxifen dosing in hormone receptor-positive metastatic breast cancer (TARGET-1): A randomized, open-label, Phase II study

  Tamura, K., Imamura, C. K., Takano, T., Saji, S., Yamanaka, T., Yonemori, K., Takahashi, M., Tsurutani, J., Nishimura, R., Sato, K., Kitani, A., Ueno, N. T., Mushiroda, T., Kubo, M., Fujiwara, Y. & Tanigawara, Y., 2020 Feb 20, In: Journal of Clinical Oncology. 38, 6, p. 558-566 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Cytochrome P-450 CYP2D6 100%
  • Tamoxifen 84%
  • Genotype 56%
  • Hormones 56%
  • 4-hydroxy-N-desmethyltamoxifen 55%
  18 Citations (Scopus)

• Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity

  Kawamura, T., Imamura, C. K., Kenmotsu, H., Taira, T., Omori, S., Nakashima, K., Wakuda, K., Ono, A., Naito, T., Murakami, H., Mushiroda, T., Takahashi, T. & Tanigawara, Y., 2020 Mar 1, In: Cancer Chemotherapy and Pharmacology. 85, 3, p. 605-614 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Gefitinib 100%
  • Non-Small Cell Lung Carcinoma 56%
  • Dose 24%
  • ErbB Receptors 7%
  • Blood Proteins 6%
  3 Citations (Scopus)

• Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer

  Tsushima, T., Kasai, H. & Tanigawara, Y., 2020 Oct 1, In: Cancer Chemotherapy and Pharmacology. 86, 4, p. 487-495 9 p.

  Research output: Contribution to journal › Article › peer-review

  • 130-nm albumin-bound paclitaxel 100%
  • Neutropenia 64%
  • Neutrophils 50%
  • Pharmacokinetics 48%
  • Serum Albumin 37%
  2 Citations (Scopus)

• Population Pharmacokinetics of Voriconazole in Patients with Invasive Aspergillosis: Serum Albumin Level as a Novel Marker for Clearance and Dosage Optimization

  Chantharit, P., Tantasawat, M., Kasai, H. & Tanigawara, Y., 2020 Dec, In: Therapeutic Drug Monitoring. 42, 6, p. 872-879 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Voriconazole 100%
  • Aspergillosis 93%
  • Serum Albumin 80%
  • Pharmacokinetics 59%
  • Population 30%
  12 Citations (Scopus)
• 2019

  Cerebrospinal pharmacokinetic and pharmacodynamic analysis of efficacy of meropenem in paediatric patients with bacterial meningitis

  Ohata, Y., Tomita, Y., Sunakawa, K., Drusano, G. L. & Tanigawara, Y., 2019 Sept, In: International journal of antimicrobial agents. 54, 3, p. 292-300 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Bacterial Meningitides 100%
  • Meropenem 99%
  • Cerebrospinal Fluid 70%
  • Pharmacokinetics 61%
  • Pediatrics 52%
  11 Citations (Scopus)

• Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer

  Kawata, T., Higashimori, M., Itoh, Y., Tomkinson, H., Johnson, M. G., Tang, W., Nyberg, F., Jiang, H. & Tanigawara, Y., 2019 May 1, In: Cancer Chemotherapy and Pharmacology. 83, 5, p. 849-858 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Gefitinib 100%
  • Interstitial Lung Diseases 69%
  • Interstitial 65%
  • Non-Small Cell Lung Carcinoma 56%
  • CL/F 28%
  12 Citations (Scopus)

• Individualized Dosing of Axitinib Based on First-Dose Area Under the Concentration–Time Curve for Metastatic Renal-Cell Carcinoma

  Miura, Y., Imamura, C. K., Uchino, K., Kishida, T., Matsubara, N., Shinojima, T., Kondo, K., Hongo, F., Yoshimura, K., Tanigawara, Y. & Takano, T., 2019 Feb, In: Clinical Genitourinary Cancer. 17, 1, p. e1-e11

  Research output: Contribution to journal › Article › peer-review

  • Axitinib 100%
  • Renal Cell Carcinoma 60%
  • Area Under Curve 51%
  • Progression-Free Survival 19%
  • Survival Rate 15%
  6 Citations (Scopus)

• Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy

  Beumer, J. H., Chu, E., Allegra, C., Tanigawara, Y., Milano, G., Diasio, R., Kim, T. W., Mathijssen, R. H., Zhang, L., Arnold, D., Muneoka, K., Boku, N. & Joerger, M., 2019 Mar, In: Clinical Pharmacology and Therapeutics. 105, 3, p. 598-613 16 p.

  Research output: Contribution to journal › Review article › peer-review

  • Drug Monitoring 100%
  • Toxicology 84%
  • Fluorouracil 82%
  • Body Surface Area 32%
  • Head and Neck Neoplasms 28%
  70 Citations (Scopus)

• Therapeutic drug monitoring of monoclonal antibodies: Applicability based on their pharmacokinetic properties

  Imamura, C. K., 2019 Feb, In: Drug Metabolism And Pharmacokinetics. 34, 1, p. 14-18 5 p.

  Research output: Contribution to journal › Review article › peer-review

  • Drug Monitoring 100%
  • Pharmacokinetics 65%
  • Monoclonal Antibodies 63%
  • Drug 45%
  • Anti-Idiotypic Antibodies 45%
  34 Citations (Scopus)
• 2018

  Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotype-Guided Dosing of Tamoxifen

  Nakamura, T., Toshimoto, K., Lee, W., Imamura, C. K., Tanigawara, Y. & Sugiyama, Y., 2018 Jul, In: CPT: Pharmacometrics and Systems Pharmacology. 7, 7, p. 474-482 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cytochrome P-450 Enzyme System 100%
  • Pharmacokinetics 76%
  • Cytochrome P-450 CYP2D6 68%
  • Genotype 63%
  • Tamoxifen 57%
  10 Citations (Scopus)

• Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non–small-cell Lung Cancer

  Kawamura, T., Kenmotsu, H., Omori, S., Nakashima, K., Wakuda, K., Ono, A., Naito, T., Murakami, H., Omae, K., Mori, K., Tanigawara, Y., Nakajima, T., Ohde, Y., Endo, M. & Takahashi, T., 2018 Mar, In: Clinical Lung Cancer. 19, 2, p. e247-e252

  Research output: Contribution to journal › Article › peer-review

  • ErbB Receptors 100%
  • Non-Small Cell Lung Carcinoma 93%
  • Protein-Tyrosine Kinases 87%
  • Mutation 58%
  • Recurrence 20%
  37 Citations (Scopus)

• Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer

  Yamauchi, T., Fernandez, J. R. E., Imamura, C. K., Yamauchi, H., Jinno, H., Takahashi, M., Kitagawa, Y., Nakamura, S., Lim, B., Krishnamurthy, S., Reuben, J. M., Liu, D., Tripathy, D., Chen, H., Takebe, N., Saya, H. & Ueno, N. T., 2018, In: Oncotarget. 9, 6, p. 6872-6882 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Breast Neoplasms 100%
  • Neoplastic Stem Cells 83%
  • Epithelial-Mesenchymal Transition 81%
  • Lapatinib 27%
  • Therapeutics 25%
  6 Citations (Scopus)

• Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker

  Mori, Y., Kasai, H., Ose, A., Serada, M., Ishiguro, M., Shiraki, M. & Tanigawara, Y., 2018 May 1, In: Osteoporosis International. 29, 5, p. 1155-1163 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Zoledronic Acid 100%
  • Tartrate-Resistant Acid Phosphatase 98%
  • Bone Resorption 77%
  • Bone Density 69%
  • Osteoporosis 67%
  18 Citations (Scopus)

• Pharmacodynamic analysis of eribulin safety in breast cancer patients using real-world postmarketing surveillance data

  Kawamura, T., Kasai, H., Fermanelli, V., Takahashi, T., Sakata, Y., Matsuoka, T., Ishii, M. & Tanigawara, Y., 2018 Sept, In: Cancer science. 109, 9, p. 2822-2829 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • eribulin 100%
  • Neutrophils 47%
  • Breast Neoplasms 38%
  • Neutropenia 36%
  • Safety 35%
  6 Citations (Scopus)
• 2017

  Dose-escalation study for the targeting of CD44v⁺ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205)

  Shitara, K., Doi, T., Nagano, O., Imamura, C. K., Ozeki, T., Ishii, Y., Tsuchihashi, K., Takahashi, S., Nakajima, T. E., Hironaka, S., Fukutani, M., Hasegawa, H., Nomura, S., Sato, A., Einaga, Y., Kuwata, T., Saya, H. & Ohtsu, A., 2017 Mar 1, In: Gastric Cancer. 20, 2, p. 341-349 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Sulfasalazine 100%
  • Neoplastic Stem Cells 81%
  • Stomach Neoplasms 66%
  • Biopsy 20%
  • Oxidative Stress 16%
  76 Citations (Scopus)

• Effect of everolimus on the glucose metabolic pathway in mouse skeletal muscle cells (C2C12)

  Yoshida, K., Imamura, C. K., Hara, K., Mochizuki, M. & Tanigawara, Y., 2017 Aug 1, In: Metabolomics. 13, 8, 98.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Everolimus 100%
  • Metabolic Networks and Pathways 57%
  • Muscle Cells 52%
  • Metabolic 46%
  • Skeletal Muscle 45%
  12 Citations (Scopus)

• Optimization of therapy by pharmacokinetic-pharmacodynamic analyses

  Imamura, C., 2017 Jan 1, Renal Cell Carcinoma: Molecular Features and Treatment Updates. Springer Japan, p. 369-381 13 p.

  Research output: Chapter in Book/Report/Conference proceeding › Chapter

  • Renal Cell Carcinoma 100%
  • Pharmacokinetics 78%
  • Imatinib 51%
  • Immunosuppressive Agent 45%
  • Gastrointestinal Stromal Tumors 41%

• Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer

  Otsubo, K., Nosaki, K., Imamura, C. K., Ogata, H., Fujita, A., Sakata, S., Hirai, F., Toyokawa, G., Iwama, E., Harada, T., Seto, T., Takenoyama, M., Ozeki, T., Mushiroda, T., Inada, M., Kishimoto, J., Tsuchihashi, K., Suina, K., Nagano, O., Saya, H., & 2 othersNakanishi, Y. & Okamoto, I., 2017 Sept, In: Cancer science. 108, 9, p. 1843-1849 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Pemetrexed 100%
  • Sulfasalazine 98%
  • Cisplatin 68%
  • Non-Small Cell Lung Carcinoma 67%
  • Neoplastic Stem Cells 26%
  37 Citations (Scopus)

• Population Pharmacokinetic and Exposure–Response Analysis of Weekly Teriparatide in Osteoporosis Patients

  Ose, A., Serada, M., Yamashita, K., Tsurui, K. & Tanigawara, Y., 2017 Dec, In: Journal of Clinical Pharmacology. 57, 12, p. 1545-1553 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Teriparatide 100%
  • Osteoporosis 62%
  • Pharmacokinetics 53%
  • Bone Density 42%
  • Area Under Curve 28%
  4 Citations (Scopus)

• Population Pharmacokinetics of Diazoxide in Children with Hyperinsulinemic Hypoglycemia

  Kizu, R., Nishimura, K., Sato, R., Kosaki, K., Tanaka, T., Tanigawara, Y. & Hasegawa, T., 2017 Nov 1, In: Hormone Research in Paediatrics. 88, 5, p. 316-323 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Diazoxide 100%
  • Hypoglycemia 70%
  • Pharmacokinetics 55%
  • Child 31%
  • Population 28%
  12 Citations (Scopus)

• The effects of advanced age and serum α₁-acid glycoprotein on docetaxel unbound exposure and dose-limiting toxicity in cancer patients

  Kenmotsu, H., Imamura, C. K., Ono, A., Omori, S., Nakashima, K., Wakuda, K., Taira, T., Naito, T., Murakami, H., Takahashi, T. & Tanigawara, Y., 2017 Nov, In: British journal of clinical pharmacology. 83, 11, p. 2416-2425 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Docetaxel 100%
  • Glycoproteins 76%
  • Acids 67%
  • Serum 40%
  • Neutropenia 35%
  13 Citations (Scopus)
• 2016

  Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study

  Booka, E., Imamura, C. K., Takeuchi, H., Hamamoto, Y., Gomi, D., Mizukami, T., Ichiyama, T., Tateishi, K., Takahashi, T., Kawakubo, H., Soejima, K., Boku, N., Tanigawara, Y. & Kitagawa, Y., 2016 Jul 1, In: Gastric Cancer. 19, 3, p. 876-886 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Fluorouracil 100%
  • Pharmacokinetics 91%
  • Prospective Studies 77%
  • Area Under Curve 70%
  • Kidney 65%
  9 Citations (Scopus)

• Evaluation of clinical response in cancer drug therapy

  Imamura, C. K., 2016, In: Japanese Journal of Clinical Pharmacology and Therapeutics. 47, 2, p. 62-67 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  1 Citation (Scopus)

• Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole

  Imamura, C. K., Furihata, K., Okamoto, S. & Tanigawara, Y., 2016 Apr 1, In: Journal of Clinical Pharmacology. 56, 4, p. 408-413 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Voriconazole 100%
  • Tacrolimus 84%
  • Cytochrome P-450 Enzyme System 76%
  • Pharmacokinetics 59%
  • Cytochrome P-450 CYP2C19 34%
  37 Citations (Scopus)
• 2015

  Dose optimization of anticancer drugs in the elderly

  Imamura, C. K., 2015 Jan 1, In: Japanese Journal of Cancer and Chemotherapy. 42, 1, p. 21-25 5 p.

  Research output: Contribution to journal › Article › peer-review

  • Elderly 100%
  • Kidney 79%
  • Pharmaceutical Preparations 61%
  • Creatinine 47%
  • Cytotoxins 33%
  1 Citation (Scopus)

• Pharmacokinetic issues on cancer pharmacotherapy

  Tanigawara, Y., 2015 Aug 1, In: Nihon rinsho. Japanese journal of clinical medicine. 73, 8, p. 1357-1363 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Imatinib Mesylate 100%
  • Pharmacokinetics 88%
  • Drug Therapy 68%
  • Drug Delivery Systems 57%
  • Pharmaceutical Preparations 48%
• 2013

  Clinical dose findings of sitafloxacin treatment: Pharmacokinetic- pharmacodynamic analysis of two clinical trial results for community-acquired respiratory tract infections

  Kohno, S., Niki, Y., Kadota, J. I., Yanagihara, K., Kaku, M., Watanabe, A., Aoki, N., Hori, S., Fujita, J. & Tanigawara, Y., 2013 Jun, In: Journal of Infection and Chemotherapy. 19, 3, p. 486-494 9 p.

  Research output: Contribution to journal › Article › peer-review

  • sitafloxacin 100%
  • Community-Acquired Infections 76%
  • Respiratory Tract Infections 53%
  • Pharmacokinetics 43%
  • Clinical Trials 37%
  16 Citations (Scopus)

• Current status of monitoring in investigator-initiated trials with IND

  Imamura, C. K., 2013 Nov 4, In: Japanese Pharmacology and Therapeutics. 41, SUPPL. 2, p. S84-S87

  Research output: Contribution to journal › Article › peer-review

• Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients

  Hirasawa, A., Zama, T., Akahane, T., Nomura, H., Kataoka, F., Saito, K., Okubo, K., Tominaga, E., Makita, K., Susumu, N., Kosaki, K., Tanigawara, Y. & Aoki, D., 2013 Dec, In: Journal of Human Genetics. 58, 12, p. 794-798 5 p.

  Research output: Contribution to journal › Article › peer-review

  • Glucuronosyltransferase 100%
  • Uridine Diphosphate 98%
  • Irinotecan 89%
  • Genes 30%
  • Neoplasms 24%
  19 Citations (Scopus)
• 2011

  A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures - A randomized, active comparator, double-blind study

  Matsumoto, T., Ito, M., Hayashi, Y., Hirota, T., Tanigawara, Y., Sone, T., Fukunaga, M., Shiraki, M. & Nakamura, T., 2011 Oct, In: Bone. 49, 4, p. 605-612 8 p.

  Research output: Contribution to journal › Article › peer-review

  • eldecalcitol 100%
  • Osteoporotic Fractures 64%
  • Cholecalciferol 63%
  • alfacalcidol 59%
  • Double-Blind Method 53%
  154 Citations (Scopus)

• How can we address cancer care after a natural disaster?

  Imamura, C. K. & Ueno, N. T., 2011 Jul, In: Nature Reviews Clinical Oncology. 8, 7, p. 387-388 2 p.

  Research output: Contribution to journal › Review article › peer-review

  • Tsunamis 100%
  • Natural Disasters 90%
  • Earthquakes 86%
  • Japan 54%
  • Chronic Disease 48%
  7 Citations (Scopus)

• Overview of the clinical pharmacokinetics of eldecalcitol, a new active vitamin D₃ derivative

  Abe, M., Tsuji, N., Takahashi, F. & Tanigawara, Y., 2011 Mar 1, In: Japanese Pharmacology and Therapeutics. 39, 3, p. 261-274 14 p.

  Research output: Contribution to journal › Review article › peer-review

  • eldecalcitol 100%
  • Cholecalciferol 63%
  • Clinical Pharmacology 43%
  • Pharmacokinetics 41%
  • Clinical Studies 25%
  14 Citations (Scopus)

• Pharmacokinetics of eldecalcitol in primary osteoporosis patients - Randomized, double-blind, multicentre, long-term phase III clinical study

  Miyata, K., Abe, M., Terao, K., Kawanishi, T., Tsuji, N., Shiraki, M., Nakamura, T., Matsumoto, T. & Tanigawara, Y., 2011 Mar 1, In: Japanese Pharmacology and Therapeutics. 39, 3, p. 299-307 9 p.

  Research output: Contribution to journal › Article › peer-review

  • eldecalcitol 100%
  • Osteoporosis 48%
  • Pharmacokinetics 41%
  • Clinical Studies 37%
  • alfacalcidol 28%
  7 Citations (Scopus)

• Population pharmacokinetics and pharmacodynamics of levofloxacin following intravenous infusion for respiratory tract infection

  Tanigawara, Y., Shimizu, T. & Totsuka, K., 2011 May 1, In: Japanese Journal of Chemotherapy. 59, SUPPL. 1, p. 55-64 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Levofloxacin 100%
  • Intravenous Infusions 79%
  • Respiratory Tract Infections 76%
  • Pharmacokinetics 61%
  • Population 32%
• 2010

  Experimental therapies: Investigator-initiated cancer trials with INDs for approval in Japan

  Imamura, C. K., Takebe, N., Nakamura, S., Saya, H. & Ueno, N. T., 2010 Mar, In: Nature Reviews Clinical Oncology. 7, 3, p. 127-128 2 p.

  Research output: Contribution to journal › Short survey › peer-review
  7 Citations (Scopus)
• 2009

  Appropriate hemodialysis scheduling based on therapeutic drug monitoring of carboplatin in a patient with lung cancer and chronic renal failure

  Kamata, H., Asano, K., Soejima, K., Shirahata, T., Nakatani, M., Inamoto, H., Iketani, O., Yamayoshi, Y., Tanigawara, Y. & Ishizaka, A., 2009 Sept, In: Japanese Journal of Cancer and Chemotherapy. 36, 9, p. 1529-1532 4 p.

  Research output: Contribution to journal › Article › peer-review

  • Drug Monitoring 100%
  • Carboplatin 97%
  • Chronic Kidney Failure 76%
  • Renal Dialysis 75%
  • Lung Neoplasms 68%
  1 Citation (Scopus)

• Population pharmacokinetics and pharmacodynamics of 500 mg oral dose levofloxacin in respiratory tract infection patients

  Tanigawara, Y., Shimizu, T. & Totsuka, K., 2009 Jul 1, In: Japanese Journal of Chemotherapy. 57, SUPPL. 2, p. 47-54 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Levofloxacin 100%
  • Respiratory Tract Infections 76%
  • Pharmacokinetics 61%
  • Population 32%
  • Microbial Sensitivity Tests 10%
  4 Citations (Scopus)
• 2008

  An open clinical study of arbekacin 200 mg q.d. in patients infected with methicillin-resistant Staphylococcus aureus (MRSA) - A clinical pharmacology study

  Aikawa, N., Kohno, S., Kaku, M., Watanabe, A., Yamaguchi, K. & Tanigawara, Y., 2008 May, In: Japanese Journal of Chemotherapy. 56, 3, p. 299-312 14 p.

  Research output: Contribution to journal › Article › peer-review

  • arbekacin 100%
  • Clinical Pharmacology 71%
  • Methicillin-Resistant Staphylococcus aureus 61%
  • Clinical Studies 41%
  • Drug-Related Side Effects and Adverse Reactions 31%
  13 Citations (Scopus)

• Efficacy, safety and pharmacokinetics of micafungin in pediatric patients with deep mycoses

  Sunakawa, K., Tsukimoto, I., Toyonaga, Y., Tsunematsu, Y., Iwai, N. & Tanigawara, Y., 2008 Mar 1, In: Japanese Journal of Chemotherapy. 56, 2, p. 190-201 12 p.

  Research output: Contribution to journal › Article › peer-review

  • Micafungin 100%
  • Mycoses 68%
  • Pharmacokinetics 50%
  • Pediatrics 43%
  • Safety 39%

• Greater impact of oral fluconazole on drug interaction with intravenous calcineurin inhibitors as compared with intravenous fluconazole

  Mihara, A., Mori, T., Aisa, Y., Yamazaki, R., Iketani, O., Tanigawara, Y., Ikeda, Y. & Okamoto, S., 2008 Jan, In: European Journal of Clinical Pharmacology. 64, 1, p. 89-91 3 p.

  Research output: Contribution to journal › Article › peer-review

  • Calcineurin Inhibitors 100%
  • Fluconazole 94%
  • Drug Interactions 79%
  • Tacrolimus 33%
  • Cyclosporine 28%
  28 Citations (Scopus)

• Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma

  Shimasaki, N., Mori, T., Torii, C., Sato, R., Shimada, H., Tanigawara, Y., Kosaki, K. & Takahashi, T., 2008 May 1, In: Journal of Pediatric Hematology/Oncology. 30, 5, p. 347-352 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Reduced Folate Carrier Protein 100%
  • Maintenance Chemotherapy 91%
  • Methylenetetrahydrofolate Reductase (NADPH2) 79%
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 60%
  • Methotrexate 59%
  53 Citations (Scopus)

• Open study of sitafloxacin in patients with respiratory tract infections - PK/PD study

  Saito, A., Tanigawara, Y., Watanabe, A., Aoki, N., Niki, Y., Kohno, S., Kaku, M., Hori, S. & Totsuka, K., 2008 Apr, In: Japanese Journal of Chemotherapy. 56, SUPPL. 1, p. 63-80 18 p.

  Research output: Contribution to journal › Article › peer-review

  • sitafloxacin 100%
  • Respiratory Tract Infections 53%
  • Streptococcus pneumoniae 19%
  • Drug-Related Side Effects and Adverse Reactions 17%
  • Diarrhea 16%
  6 Citations (Scopus)
• 2007

  Phase III study of garenoxacin in patients with secondary infection of chronic respiratory diseases

  Kobayashi, H., Tanigawara, Y., Watanabe, A., Aoki, N., Sano, Y., Odagiri, S., Niki, Y., Kohno, S. & Saito, A., 2007 Oct, In: Japanese Journal of Chemotherapy. 55, SUPPL. 1, p. 144-161 18 p.

  Research output: Contribution to journal › Article › peer-review

  • garenoxacin 100%
  • Coinfection 55%
  • Chronic Disease 42%
  • Streptococcus pneumoniae 29%
  • Pharmacokinetics 21%
  5 Citations (Scopus)

• Reversal effects of Ca²⁺ antagonists on multidrug resistance via down-regulation of MDR1 mRNA

  Komoto, C., Nakamura, T., Yamamori, M., Ohmoto, N., Kobayashi, H., Kuwahara, A., Nishiguchi, K., Takara, K., Tanigawara, Y., Okamura, N., Okumura, K. & Sakaeda, T., 2007, In: Kobe Journal of Medical Sciences. 53, 6, p. 355-363 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Vinblastine 100%
  • Multiple Drug Resistance 86%
  • Down-Regulation 57%
  • Daunorubicin 52%
  • Digoxin 48%
  10 Citations (Scopus)
• 2006

  Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma

  Shimasaki, N., Mori, T., Samejima, H., Sato, R., Shimada, H., Yahagi, N., Torii, C., Yoshihara, H., Tanigawara, Y., Takahashi, T. & Kosaki, K., 2006 Feb 1, In: Journal of Pediatric Hematology/Oncology. 28, 2, p. 64-68 5 p.

  Research output: Contribution to journal › Article › peer-review

  • Reduced Folate Carrier Protein 100%
  • Methylenetetrahydrofolate Reductase (NADPH2) 79%
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 60%
  • Methotrexate 59%
  • Child 26%
  90 Citations (Scopus)

• Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections

  Tabata, K., Katashima, M., Kawamura, A., Tanigawara, Y. & Sunagawa, K., 2006, In: Biological and Pharmaceutical Bulletin. 29, 8, p. 1706-1711 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Micafungin 100%
  • Mycoses 53%
  • Pharmacokinetics 39%
  • Metabolite 37%
  • Pediatrics 33%
  31 Citations (Scopus)

• Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors

  Yamada, Y., Tamura, T., Yamamoto, N., Shimoyama, T., Ueda, Y., Murakami, H., Kusaba, H., Kamiya, Y., Saka, H., Tanigawara, Y., McGovren, J. P. & Natsumeda, Y., 2006 Aug, In: Cancer Chemotherapy and Pharmacology. 58, 2, p. 173-182 10 p.

  Research output: Contribution to journal › Article › peer-review

  • edotecarin 100%
  • EC 5.99.1.2 (DNA Topoisomerase) Inhibitor 71%
  • Topoisomerase I Inhibitors 67%
  • Dose 35%
  • Pharmacokinetics 35%
  23 Citations (Scopus)